Brief: Krystal Biotech Announces Early Evidence Of Monotherapy Activity In Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer

Krystal Biotech

18/12/2024 13:33

Dec 18 (Reuters) - Krystal Biotech Inc  KRYS.O :
    * KRYSTAL BIOTECH ANNOUNCES EARLY EVIDENCE OF MONOTHERAPY
ACTIVITY
IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED NON-SMALL CELL
LUNG CANCER
    * REPORTS 27% ORR AND 73% DCR IN NSCLC TRIAL
    * MAJORITY OF TREATMENT-RELATED ADVERSE EVENTS BEEN MILD TO
MODERATE IN SEVERITY & TRANSIENT, WITH NO GRADE 4 OR 5 ADVERSE
EVENTS OBSERVED

Source text:  ID:nGNX3mDtjH 
Further company coverage:  KRYS.O 

 ((Reuters.Briefs@thomsonreuters.com;))